Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)

PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate.

Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT.

Phathom Pharma's Q3 2025 earnings beat expectations. Revenue hit $49.5M, and its EPS loss narrowed to $0.15. The company also raised its full-year 2025 revenue guidance.

Phathom Pharmaceuticals (PHAT) beats Q2 revenue and EPS estimates, driven by strong VOQUEZNA adoption. Shares rise 6.2% premarket as company narrows losses and raises full-year guidance.

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.